IGMS Stock Overview
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases.
Snowflake Score | |
---|---|
Valuation | 1/6 |
Future Growth | 2/6 |
Past Performance | 0/6 |
Financial Health | 6/6 |
Dividends | 0/6 |
My Notes
NewNotes are coming soon
IGM Biosciences, Inc. Competitors
Price History & Performance
Historical stock prices | |
---|---|
Current Share Price | US$22.30 |
52 Week High | US$35.98 |
52 Week Low | US$12.67 |
Beta | -0.19 |
1 Month Change | 18.11% |
3 Month Change | -12.14% |
1 Year Change | 25.56% |
3 Year Change | -50.81% |
5 Year Change | n/a |
Change since IPO | -8.23% |
Recent News & Updates
Recent updates
Here's Why We're Not At All Concerned With IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Jan 05IGM Biosciences (NASDAQ:IGMS) Is In A Strong Position To Grow Its Business
Sep 23IGM Biosciences started at BofA Securities with a buy on IgM antibody candidates
Aug 29IGM Biosciences GAAP EPS of -$1.33 misses by $0.93, revenue of $0.4M
Aug 08We're Keeping An Eye On IGM Biosciences' (NASDAQ:IGMS) Cash Burn Rate
Jun 09IGM Biosciences: Interesting Science, Poor Trial Data
Feb 23Is IGM Biosciences (NASDAQ:IGMS) In A Good Position To Deliver On Growth Plans?
Feb 17Here's Why We're Not Too Worried About IGM Biosciences' (NASDAQ:IGMS) Cash Burn Situation
Sep 07IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
May 25IGM Biosciences (NASDAQ:IGMS) Is In A Good Position To Deliver On Growth Plans
Feb 08IGM Biosciences reports quick assets and provides business updates
Jan 13Trade Alert: The Independent Director Of IGM Biosciences, Inc. (NASDAQ:IGMS), M. Behrens, Has Just Spent US$4.0m Buying 39% More Shares
Dec 18IGM Bio prices upsized $200M public offering
Dec 09IGM Biosciences proposes public offering
Dec 07IGM Biosciences (IGMS) Investor Presentation - Slideshow
Nov 20Shareholder Returns
IGMS | US Biotechs | US Market | |
---|---|---|---|
7D | -12.2% | -1.8% | -1.8% |
1Y | 25.6% | 1.9% | -10.9% |
Return vs Industry: IGMS exceeded the US Biotechs industry which returned 2.9% over the past year.
Return vs Market: IGMS exceeded the US Market which returned -10.8% over the past year.
Price Volatility
IGMS volatility | |
---|---|
IGMS Average Weekly Movement | 16.2% |
Biotechs Industry Average Movement | 11.9% |
Market Average Movement | 6.6% |
10% most volatile stocks in US Market | 17.3% |
10% least volatile stocks in US Market | 2.8% |
Stable Share Price: IGMS is more volatile than 75% of US stocks over the past 3 months, typically moving +/- 16% a week.
Volatility Over Time: IGMS's weekly volatility (16%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
Founded | Employees | CEO | Website |
---|---|---|---|
1993 | 242 | Fred Schwarzer | https://igmbio.com |
IGM Biosciences, Inc., a biotechnology company, develops Immunoglobulin M (IgM) antibodies for the treatment of cancer, infectious diseases, and autoimmune and inflammatory diseases. The company’s lead product candidate is IGM-2323, a bispecific IgM antibody that is in Phase 2 clinical trials to treat patients with relapsed/refractory B cell Non-Hodgkin’s lymphoma (NHL). It is also developing IGM-8444, an IgM antibody, which is in Phase 1 clinical trials for the treatment of patients with solid cancers; and IGM-7354, an anti-PD-L1 IgM antibody for the treatment of patients with solid and hematologic malignancies; IGM-2644, a bispecific T cell engaging IgM antibody targeting CD38 and CD3 proteins for the treatment of patients with multiple myeloma; and IGM-2537, a bispecific T cell engaging IgM antibody targeting CD123 and CD3 proteins for the treatment of patients with acute myeloid leukemia, myelodysplastic syndromes, and acute lymphoblastic leukemia.
IGM Biosciences, Inc. Fundamentals Summary
IGMS fundamental statistics | |
---|---|
Market Cap | US$955.03m |
Earnings (TTM) | -US$219.17m |
Revenue (TTM) | US$697.00k |
1,370x
P/S Ratio-4.4x
P/E RatioIs IGMS overvalued?
See Fair Value and valuation analysisEarnings & Revenue
IGMS income statement (TTM) | |
---|---|
Revenue | US$697.00k |
Cost of Revenue | US$46.42m |
Gross Profit | -US$45.72m |
Other Expenses | US$173.45m |
Earnings | -US$219.17m |
Last Reported Earnings
Sep 30, 2022
Next Earnings Date
n/a
Earnings per share (EPS) | -5.12 |
Gross Margin | -6,559.25% |
Net Profit Margin | -31,444.48% |
Debt/Equity Ratio | 0% |
How did IGMS perform over the long term?
See historical performance and comparison